Search

everythinglearnresearchcommunity

for

Search:↓

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Nanozymes show promise for effective and safe cancer treatment.

Tofacitinib, a hair regrowth treatment, may worsen acne.

More research is needed to understand chemotherapy-induced hair loss and its phases.

Temozolomide can cause severe bone marrow suppression, leading to life-threatening complications.

KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.

Inducing survivin in normal tissues can protect against radiation damage.

Acne patients have higher skin mTORC1 activity, which is reduced by isotretinoin treatment.

Tofacitinib treatment for hair loss may worsen acne.

Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.

Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

JAK inhibitors show promise for treating various skin diseases.

ATP helps prevent skin damage from vandetanib by reducing stress.

New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Sorafenib can cause a unique skin reaction.

Targeting Sirt1 can reduce androgen levels and slow glioblastoma growth.

CTP-543 is generally safe for treating alopecia areata.

Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

These new skin treatments are safer and more effective with minimal side effects.